Diffuse Glioma
13
5
8
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
7.7%
1 terminated out of 13 trials
0.0%
-86.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (13)
Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Vorasidenib Expanded Access Program
Administration of Repurposed Ketoconazole in Glioma Patients
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma
18F-Fluciclovine PET-MRI in High-grade Glioma
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
Phase I Study of Marizomib + Panobinostat for Children With DIPG
RE-irradiation of Diffuse MIdline Glioma paTients